Skip to content

The Comparison of anti-inflammatory versus supplement dose of selenium in mild Graves' orbitopathy

The Comparison of anti-inflammatory versus supplement dose of selenium in mild Graves' orbitopathy

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
TCTR
Registry ID
TCTR20180228005
Enrollment
87
Registered
2018-02-28
Start date
2018-03-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Clinical activity score Graves&#39

Interventions

The selenium supplementation with a daily dose of 70 micrograms one capsule per oral in the morning for 6 months.,The selenium supplementation with a daily dose of 200 micrograms one capsule per oral
Placebo Comparator Dietary Supplement,Placebo Comparator Dietary Supplement,Sham Comparator Dietary Supplement
70 Selenium supplementation,200 Selenium supplementation,Placebo

Sponsors

Ratchadapiseksompotch Research fund
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: - Mild thyroid eye disease group according to EUGOGO recommendation - Age above 18 years old - Normal thyroid hormone level (FT4, FT3) for at least 6 months - Thyroid eye symptoms less than 24 months

Exclusion criteria

Exclusion criteria: - Allergic reaction to selenium - History of selenium use - Pregnant or breast-feeding - Recent history of orbital and eyelid surgery of less than 6 months

Design outcomes

Primary

MeasureTime frame
Graves clinical activity score 0,6 months EUGOGO Graves clinical activity scaling

Secondary

MeasureTime frame
Graves' Quality of life 0,3,6 months Graves' Quality of life Questionaire

Countries

Thailand

Contacts

Public ContactPreamjit Saonanon

Ophthalmology department, Chulalongkorn hospital

drpreamjit@gmail.com022564142

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026